Drug Approval | August 03, 2022
USFDA issues 3 observations for Aurobindo Pharma’s Unit XI
The company has responded to the warning letter and carried out the committed corrections.
The company has responded to the warning letter and carried out the committed corrections.
The region's digital health market, valued at USD 40.3 billion in 2021, is expected to expand to USD 326.7 billion by 2030 at a CAGR of 26.5 per cent.
DS-7300 is a specifically designed potential first-in-class B7-H3 directed antibody drug conjugate
ICRA expects the OPM of the sample set to moderate to 20.2% in FY2023 from 21.5% in FY2022.
The appointments will add to the well-diversified experience that currently exists on the PPL board.
The US FDA has determined that the inspection classification of the facility is Voluntary Action Indicated
The FDA informed Astellas that it did not have sufficient information to assess the risks to subjects
It´s the first trial to demonstrate the benefits of dual pathway inhibition
Agreement to co-develop artificial intelligence (AI) technology for the application in peptide drug design
Cantourage introduces second Clever Leaves medical cannabis product to the German market
Subscribe To Our Newsletter & Stay Updated
